The Breast Cancer Patient Education Act (BCPEA), passed by Congress in December 2015, is federal legislation aimed at improving awareness of certain rights afforded to breast cancer patients. The Women’s Health Care and Cancer Rights Act, enacted in 1998, requires health plans that provide coverage for breast cancer care to include coverage for breast reconstruction. However, many patients remain unaware of this right. The goal of the BCPEA is to help spread this information to breast cancer patients.
Raven Quinn, a Los Angeles-based singer-songwriter, recently released her third album The Acoustic EP. While you may be surprised to find music news on our blog, this album holds special significance for Raven and for us. It was the first album she released since her breast cancer diagnosis in June of 2015, and she is graciously donating one-half of all proceeds to breast cancer research through the Cancer Research Collaboration, a non-profit working with Breastlink Medical Group.
The album is available worldwide on iTunes, Amazon.com, and everywhere digital music is sold. Signed and personalized physical copies of the album are available in Raven’s store at www.ravenquinn.com. CDs can also […]
Nimmi Kapoor, MD, a fellowship-trained, board-certified oncology surgeon, has been appointed Medical Director of Breastlink at the Encino Breast Care Center. Breastlink will relocate to the Integrated Cancer Institute when construction is completed in 2016.
A Multidisciplinary Approach to Breast Cancer Care
Breastlink was established in 1995 by Dr. John Link, a medical oncologist, who helped to develop one of the nation’s first comprehensive breast health centers at Long Beach Memorial Medical Center. The Breastlink approach to breast cancer care incorporates the expertise of breast cancer specialists in oncology, imaging, surgery and reconstruction surgery. Women treated with this multidisciplinary model benefit from the collective expertise of a team specifically dedicated to breast […]
The long-term survival rate for women diagnosed with ductal carcinoma in situ (DCIS) or non-invasive breast cancer is excellent, according to a new study released in August. The study, “Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ” revealed that this held true regardless of the type of treatment. […]
Lisa E. Guerra, MD, a fellowship-trained breast-dedicated surgeon, recently joined Breastlink and will work out of our new location in Newport Beach. Dr. Guerra has spent the last seven years serving Newport Beach patients as a surgeon at the Hoag Breast Center. Her background in oncoplastic surgery, intraoperative radiation therapy and risk management will make Dr. Guerra a valuable addition to the Breastlink team. […]
For more than 20 years, the multidisciplinary team at Breastlink has provided comprehensive breast health services to the women of Orange County. With locations in Orange, Laguna Hills and Murrieta, Breastlink has expanded to Newport Beach. Now, even more women can benefit from Breastlink services at a location convenient to them. […]
Medical advancements allow us to treat breast cancer more effectively than ever before. However, side effects can occur as a result of treatment. Many breast cancer patients receive some combination of surgery, radiation therapy and chemotherapy. Chemotherapy side effects can range from being a temporary nuisance to having a sustained negative impact on quality of life. As oncologists, it is our job to help patients avoid, lessen or completely eliminate such side effects. […]
Breastlink Partners with Researchers to Explore Atezolizumab in Triple-Negative Breast Cancer Patients
Breastlink has partnered with researchers to explore an investigational cancer immunotherapy called atezolizumab (MPDL3280A) in the treatment of metastatic triple-negative breast cancer. In early-stage trials, atezolizmab was effective in patients previously treated for triple-negative breast cancer. A new trial will investigate atezolizumab with chemotherapy in metastatic triple-negative breast cancer patients who have not received prior systemic therapy for incurable disease. […]